3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 32026-09-29NCT06881784
Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic PurpuraCytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, acquired thrombotic thrombocytopenic purpura, blood coagulation disease, blood platelet disease, hematologic disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombophilia, thrombotic microangiopathy, thrombotic thrombocytopenic purpuraActive, not recruitingNot stated2026-02-11NCT05046717
Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain MetastasesNeoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, brain disorder, central nervous system cancer, central nervous system disorder, melanocytic neoplasm, melanoma, neoplasm, nervous system disorder, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasmRecruitingPhase 22025-10-01NCT06887088